Acadia Pharmaceuticals Inc. today announced that the journal Med published results from the open-label study, DAFFODILtm, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® ...

Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study ...

Healthcare analysts believe that shares in rare neurological share play Neuren Pharmaceuticals are well undervalued after a ...

At just 26 months old, Grace Visser was diagnosed with Rett Syndrome, a rare genetic disorder that affects brain development.

A visitor tries a surgery robot at the booth of Fosunpharma at the Medical Equipment & Healthcare Products Exhibition Area during the 7th China International ...

When Ms. Liu, a cancer patient, picked up a box of medication at the hospital pharmacy, she felt an overwhelming sense ...

Q4 2024 Earnings Call Transcript February 26, 2025 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Ladies and gentlemen, good ...

Turner syndrome is a rare genetic disorder found in some women and people assigned female at birth. It can cause short stature and a range of health issues including heart defects, learning ...

Reports FY24 revenue $8.333M vs $15.451M last year. “We are pleased with the pace at which our TSHA-102 clinical program is advancing across a ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...

Neuren Pharmaceuticals (ASX:NEU) has received a Rare Paediatric Disease Designation from the US FDA for NNZ-2591 in ...

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day. About Anavex Life ...